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Supercritical CO2 antisolvent crystallization typically promotes the formation of metastable 
polymorphic forms of pharmaceutical drugs. However, using this technological approach in 
combination with the use of distinct molecular additives can provide further control over the 
final polymorphic form obtained. The work presented herein investigates the influence of 
critical processing variables of a CO2 antisolvent crystallization process in the presence of 
molecular additives with respect to polymorphism of carbamazepine (CBZ), a highly 
polymorphic BCS class II drug. A Design of Experiments (DoE) approach was performed to 
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assess the outcome of CBZ polymorphism, impacted by CO2 antisolvent processing 
variables such as pressure, temperature and CO2 addition rate when anionic additives 
(sodium stearate or sodium dodecyl sulfate) were selected. Statistical analysis revealed that 
the combination of temperature and CO2 addition rate show statistically significant impact (p 
< 0.05) on the final CBZ polymorphic form obtained when no additive was present during 
short hold studies. However, when using 5% w/w additive in the CBZ methanol solutions, 
CBZ samples produced from CO2 antisolvent crystallization correspond to form II (when 
using sodium stearate as the additive) or form III (when using sodium dodecyl sulfate as the 
additive) for most samples, regardless of the processing conditions used. An investigation 
into the polymorphic stability of these CBZ samples was undertaken, allowing the 
precipitated CBZ to remain immersed in the supercritical media (supercritical CO2 and 
methanol) for a prolonged period (sixty hours). Carbamazepine samples that were initially 
form II, began to convert to the stable form III at lower temperature (40 °C), while samples 
that were initially form III showed almost no conversion.
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Gas antisolvent crystallization, supercritical fluid, supersaturation, active pharmaceutical 
ingredient, polymorph control, design of experiments.
Introduction
The ability of an active pharmaceutical ingredient (API) to crystallize in different structural 
arrangements, named polymorphs, has generated significant attention from the pharmaceutical 
industry over the last 20 years. Pharmaceutical polymorphism is a critical control objective in 
crystallization processes which is known to play a major role in determining drug product attributes 
including solubility, stability and rheological behavior during downstream processing.1, 2 
Poorly soluble compounds represent 40% of the top 200 oral drugs marketed in the US and 
90% of new chemical entities (NCEs), emphasizing the necessity for establishing comprehensive 
methods to increase the bioavailability of these compounds.3-6 The ability to control the polymorphism 
of an API represents a potential solution to address the concerning issue of poorly soluble polymorphic 
APIs, as metastable forms typically demonstrate a higher solubility profile than stable forms. The 
polymorphic form of an API obtained from a pharmaceutical crystallization process can be affected 
by several processing parameters such as temperature, pressure, supersaturation, type of solvent and 
presence of molecular additives.7-9 Additives have been shown to affect the crystallization kinetics, 
namely the growth, of polymorphic materials.10-14 In these cases, additives incorporate themselves, 
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stereoselectively, into growing faces of crystals, thereby inhibiting further growth of these faces, 
promoting the appearance/growth of other polymorphic forms.14, 15 To date, the detailed mechanisms 
involved in additive-mediated pharmaceutical crystallization methods are still unknown in many 
instances but potentially provide the opportunity to combat the poor API solubility concerns present 
in the pharmaceutical industry.16 
The properties of supercritical fluids (SCF) have been investigated by many authors with a 
perspective towards solid-sate control and particle engineering of pharmaceutical compounds.16-22 
Supercritical CO2 (scCO2) is the most commonly used SCF due to its low cost and high abundance, 
as well as its low critical temperature (31.1°C) and pressure (74.8 bar).23, 24 Additionally, scCO2 is 
non-toxic and can reduce the quantities of organic solvent required for processing.19, 25, 26 Supercritical 
CO2 has three unique roles that make it suitable for pharmaceutical processing.20 The first relates to 
the solvent capacity of scCO2, which typically reduces or eliminates the requirement for organic 
solvents for API production. The second role is the atomization enhancement ability of scCO2, where 
solvent-free particles can be produced at mild processing conditions. The final role, which is discussed 
in this study and is the most commonly reported use, relates to the antisolvent capacity of scCO2.16, 24, 
27-31 The decision on which scCO2 role to select can depend on various factors but is heavily influenced 
by the solubility of the organic solvent and API in scCO2.
Carbamazepine (CBZ) is a BCS class II drug discovered in 1960 and used to treat epilepsy, 
neuropathic pain and schizophrenia.32 There are four anhydrous forms of CBZ which have the 
following relative thermodynamic stabilities (at room temperature): III > I > IV > II.33-35 An 
enantiotropic relationship between CBZ forms I and III has been determined, alongside a transition 
temperature of 71 °C between these two polymorphs.36 The solubility of these two polymorphs in 
simulated gastric fluids and particularly scCO2 has been reported by Kalikin et al. and Bettini et al.37-39 
Bettini et al. which demonstrated that at pressures below 150 bar, both polymorphs show a similar 
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solubility in scCO2 at 40 °C and 55 °C; and it is not until 300 bar at 55 °C that there is a significant 
difference in solubilities observed.38  Due to the quick transformation of other metastable forms, such 
as CBZ form II, it is not possible to determine its melting point or thermodynamic relationship to other 
CBZ polymorphs.40 With great emphasis being placed on polymorphic monitoring and control of APIs 
by the pharmaceutical industry, numerous studies have been conducted to attempt to identify 
timeframes when polymorphic transformation will occur under the influence of various processing 
conditions.41-43
In this work, a gas antisolvent (GAS) crystallization process is used to crystallize distinct CBZ 
polymorphic forms from methanol solutions containing molecular additives. This technique (GAS) is 
typically employed when an API has a low solubility in scCO2 and the organic solvent is readily 
miscible with scCO2.16, 19, 20, 29, 38, 44, 45 Padrela et al. reported the polymorphic control of CBZ 
through the use of anionic additives in a supercritical antisolvent crystallization method at specific 
operating conditions.16 This control was achieved by using the GAS method and demonstrated that 
both stable and metastable forms of CBZ could be obtained when using distinct molecular additives 
such as sodium dodecyl sulfate (SDS) and sodium stearate (SS), respectively. Padrela et al. also 
performed molecular modeling using density functional theory (DFT) to gain insight into the 
molecular mechanisms by which the additives governed the polymorphic outcome of CBZ.16 It was 
suggested that CBZ molecules arrange themselves (during a pre-nucleation stage) in different 
formations depending on the additive selected, and template the crystallization of distinct polymorphic 
forms.16 
This paper aims to investigate how robust the polymorphic control of CBZ, exhibited by 
anionic additives (e.g. sodium stearate, sodium dodecyl sulfate), can be across a range of distinct 
operating variables. The processing variables that were selected for this study include temperature, 
pressure and scCO2 addition rate. The polymorphic stability of precipitated CBZ particles while 
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immersed in scCO2 for an extended period is also investigated in this study to determine the degree 
of control achievable with the additives sodium stearate (SS) and sodium dodecyl sulfate (SDS).
Experimental Section
Materials
Carbamazepine (verified to be Form III by reflection powder X-ray diffraction), sodium 
stearate, sodium dodecyl sulfate, ethyl cellulose and methanol were purchased from Sigma 
Aldrich and used without further purification (purity was >99.9%). The molecular structures 
of carbamazepine and both anionic additives (sodium stearate and sodium dodecyl sulfate) 
are presented in Figure 1 and are discussed in the supporting information for SEM-EDS 
analysis. Carbon dioxide (99.98%) was supplied by BOC (Ireland).
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Figure 1. Molecular structure of a) carbamazepine, b) sodium stearate and c) sodium dodecyl 
sulfate.
Solution Preparation
Carbamazepine (CBZ) with/without additives was dissolved in methanol (70.0 mg in 1 mL of 
methanol). The sample was placed in an ultrasonic water bath for 5 minutes to ensure complete 
dissolution of solid material. When additives were selected for the preparation of the CBZ 
solutions, 5% w/w (~3.5 mg) of each additive were added to the CBZ solutions. Each solution 
was then filtered through a 0.2 μm pore size nylon filter (Whatman Inc.) to remove any 
undissolved material. 
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Gas Antisolvent (GAS) Crystallization
Figure 2 presents a schematic diagram of a custom-designed batch gas antisolvent (GAS) 
apparatus.
Figure 2. Schematic diagram of the gas antisolvent (GAS) apparatus. 1, CO2 cylinder; 2, gas 
compressor; 3, temperature-controlled air chamber; 4, stainless steel storage cylinder; 5, 
pressure transducer; 6, high-pressure vessel; 7, magnetic stirrer plate; 8, exit valve. 
The GAS apparatus presented in Fig. 2 comprises of a 100 cm3 stainless steel storage vessel 
and a 10 cm3 stainless steel high-pressure reaction vessel (where crystallization occurs) with 
monitored temperature and pressure using a T-type thermocouple and a pressure 
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transducer (Omega model PX603), respectively. These vessels were placed inside a 
temperature-controlled air chamber to maintain the scCO2 properties and ongoing reaction 
at the desired temperature. A borosilicate window was fitted on the top of the high-pressure 
vessel for visualization purposes during the experiments. 
A Teledyne ISCO 260D pump was used to compress the CO2 before discharging it into the 
storage vessel and allowing it to remain in this vessel for a short period of time (~10 minutes) 
until it reached the desired temperature. A solution containing 70 mg of CBZ dissolved in 
1mL of methanol with/without additive was placed inside the high-pressure reaction vessel 
and sealed.  Previous studies have demonstrated that precipitation of this API (CBZ) using 
the GAS process can be achieved at lower concentrations (50 mg/ml). The work in this 
manuscript will be conducted at a higher temperature than the study referenced16, therefore 
higher pressure may be required to induce precipitation and, as a result, a higher initial 
concentration was selected for this study to compensate for this. Supercritical CO2 (scCO2) 
was then allowed to flow into the high-pressure vessel at a pre-determined addition rate 
(0.01-1.52 g/s) until the desired pressure was reached, so that antisolvent crystallization 
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could occur. As scCO2 entered the vessel, the solutions were subjected to magnetic stirring 
at 600 rpm to ensure appropriate miscibility between the antisolvent (scCO2) and the API 
solution occurs. When supersaturation was reached, and crystallization occurred, magnetic 
stirring was turned off and the exit valve (number 8 in Figure 2) was opened to continuously 
flush scCO2 through the high-pressure vessel, thereby allowing methanol to evaporate into 
the scCO2 and be removed from the vessel. At certain conditions (70 °C, 90 bar, described 
in Tables 1 and 2), antisolvent supersaturation did not immediately occur as there was an 
insufficient amount of CO2 to induce precipitation. However, upon flushing scCO2 through 
the vessel for a period of time (approximately 2 minutes) and allowing methanol to evaporate 
and be removed, precipitation, caused by a combination of antisolvent supersaturation and 
evaporation could be observed. The scCO2 was passed through the reaction vessel over a 
1-hour time frame at a flow-rate of approximately 5 g/min (dependent on the pressure and 
temperature value). After the solvent flushing had concluded, the high-pressure vessel was 
slowly depressurized, and the resulting material was collected.
The samples obtained from the GAS experiments were stored in a desiccator prior to their 
characterization. Table 1 presents the experimental conditions used in the preparation of 
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the CBZ solutions prior to being processed by the gas antisolvent (GAS) technique.
Design of Experiments (DoE) 
A study using 3-factor 2-level full factorial Design of Experiments (DoE) with center points 
was performed to investigate the influence of the variable GAS processing variables (pressure, 
temperature and CO2 antisolvent addition rate) and solution properties (with/without additive) on the 
polymorphism of CBZ crystals. A DoE without the use of additives was first performed before 
investigating the impact of additives (Tables 1 and 2; Figure 4). Sodium stearate (SS) and sodium 
dodecyl sulfate (SDS) were the additives used in the DoE study (Tables 1 and 2; Figures 5 and 6), as 
it has been reported recently that these additives promote the formation of PXRD-pure CBZ forms II 
and III, respectively at specific conditions.16 
Table 1. Experimental Conditions Used in Gas Antisolvent (GAS) Experiments for the 
Crystallization of Carbamazepine (CBZ) from Methanol Solutions using a Short-Hold Design 







P       
(MPa)






DoE Point 1 No Additive - 9.0 40 0.01 III
DoE Point 2 No Additive - 17.0 40 0.01 III
DoE Point 3 No Additive - 17.0 40 1.52 II and III
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DoE Point 4 No Additive - 9.0 40 1.52 II and III
DoE Point 5 No Additive - 13.0 55 0.77 II and III
DoE Point 6 No Additive - 9.0 70 0.01 I, II and III
DoE Point 7 No Additive - 17.0 70 0.01 III
DoE Point 8 No Additive - 17.0 70 1.52 III
DoE Point 9 No Additive - 9.0 70 1.52 III
DoE Point 10 SS 5 9.0 40 0.01 II
DoE Point 11 SS 5 17.0 40 0.01 II
DoE Point 12 SS 5 17.0 40 1.52 II
DoE Point 13 SS 5 9.0 40 1.52 II
DoE Point 14 SS 5 13.0 55 0.77 II
DoE Point 15 SS 5 9.0 70 0.01 II
DoE Point 16 SS 5 17.0 70 0.01 II
DoE Point 17 SS 5 17.0 70 1.52 II
DoE Point 18 SS 5 9.0 70 1.52 II
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DoE Point 19 SDS 5 9.0 40 0.01 III
DoE Point 20 SDS 5 17.0 40 0.01 III
DoE Point 21 SDS 5 17.0 40 1.52 III
DoE Point 22 SDS 5 9.0 40 1.52 III
DoE Point 23 SDS 5 13.0 55 0.77 III
DoE Point 24 SDS 5 9.0 70 0.01 II and III
DoE Point 25 SDS 5 17.0 70 0.01 III
DoE Point 26 SDS 5 17.0 70 1.52 III
DoE Point 27 SDS 5 9.0 70 1.52 III
aCAdditive: proportion of additive used; P: pressure; T: temperature; RAddition Rate: addition rate of scCO2 
into the high-pressure vessel; SS: Sodium Stearate; SDS: Sodium dodecyl sulfate. For all DoE points, 
concentration of CBZ in methanol was 70 mg/ml and stirring rate was 600 RPM. Once antisolvent 
crystallization occurred, scCO2 was immediately flushed through the reactor for 1 hour at a rate of 
approximately 5 g/min (10 ml/min).
An additional study to monitor the polymorphic form obtained over a longer period was also 
undertaken. In these experiments (described in Table 2), once anti-solvent crystallization 
occurred and the CBZ particles precipitated, the high-pressure vessel remained pressurized 
with the drug suspension immersed in scCO2 for an additional sixty hours. Upon completion 
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of this period, the solvent was removed with continuous scCO2 flushing as described 
previously.
Table 2. Experimental Conditions Used in Gas Antisolvent (GAS) Experiments for the 








P         
(MPa)





















- 9.0 40 1.52 III
DoE Point 32 No - 13.0 55 0.77 III
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- 9.0 70 1.52 I and II
DoE Point 37 SS 5 9.0 40 0.01 II and III
DoE Point 38 SS 5 17.0 40 0.01 III
DoE Point 39 SS 5 17.0 40 1.52 III
DoE Point 40 SS 5 9.0 40 1.52 II and III
DoE Point 41 SS 5 13.0 55 0.77 II
DoE Point 42 SS 5 9.0 70 0.01 II 
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DoE Point 43 SS 5 17.0 70 0.01 II
DoE Point 44 SS 5 17.0 70 1.52 II
DoE Point 45 SS 5 9.0 70 1.52 II
DoE Point 46 SDS 5 9.0 40 0.01 III
DoE Point 47 SDS 5 17.0 40 0.01 III
DoE Point 48 SDS 5 17.0 40 1.52 III
DoE Point 49 SDS 5 9.0 40 1.52 III
DoE Point 50 SDS 5 13.0 55 0.77 III
DoE Point 51 SDS 5 9.0 70 0.01 III
DoE Point 52 SDS 5 17.0 70 0.01 III
DoE Point 53 SDS 5 17.0 70 1.52 III
DoE Point 54 SDS 5 9.0 70 1.52 I and III
bCAdditive: proportion of additive used; P: pressure; T: temperature; RAddition Rate: addition rate of scCO2 
into the high-pressure vessel; SS: Sodium Stearate; SDS: Sodium dodecyl sulfate. For all DoE points, 
concentration of CBZ in methanol was 70 mg/ml and stirring rate was 600 RPM. Once antisolvent 
crystallization occurred, scCO2 and the drug suspension remained in the high-pressure vessel for a 
period of sixty hours, after which scCO2 was flushed through the reactor for 1 hour at a rate of 
approximately 5 g/min (10 ml/min).
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PXRD in reflection mode was performed using an Empyrean diffractometer (PANalytical, Phillips) 
with Cu Kα radiation (λ = 1.5406 Å) at room temperature. Samples were lightly ground and pressed 
on a zero-background plate prior to analysis. Data was recorded at a tube voltage of 40 kV and a tube 
current of 40 mA, with a step size of 0.02° (2θ) and a scan speed of 0.102° (2θ·s–1) in the angular 
range of 5° to 30° (2θ) with 4 rpm.
Scanning Electron Microscopy (SEM) analysis was performed on a Hitachi SU-70 system operating 
at 10 kV. Samples were mounted onto aluminum stubs with double-sided carbon tape. The stubs were 
placed inside a gold sputter coater (Emitech K550X) and coated with a plasma current of 20 mA for 
two minutes. Chemical composition was investigated by using SEM Oxford instruments EDS 
detector where the atomic % of specific elements (nitrogen, oxygen and sodium) at multiple 
points, relative to one another, was determined in addition to atomic mapping of specific 
elements. This elemental analysis is discussed in the supporting information.
Results and Discussion
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Design of Experiments (DoE)
The gas antisolvent (GAS) process variables investigated in this study were temperature, 
pressure and scCO2 addition rate. These factors were selected for the DoE as they typically 
represent critical operating conditions that influence crystal growth and polymorphism. 
Pressure and temperature can affect the density of CO2, thereby influencing its solvating 
power/miscibility in the organic solvent and consequently impacting supersaturation levels 
of the API solutions. As a result of the  transition temperature (71 °C) between form I and III, 
a maximum operating temperature of 70 °C was chosen for the DoEs studied in this work 
(see Figure 3). As the critical temperature of CO2 is 31.1 °C, a minimum working temperature 
of 40 °C was selected to ensure that the CO2 remains in a supercritical state.
The maximum pressure for this study was determined by the pressure rating of the high-
pressure vessel (200 bar); therefore, 170 bar was selected as the maximum working 
pressure in the event of a pressure increase by external factors (e.g. temperature). The 
maximum pressure determination was also chosen to understand the influence of increased 
supersaturation on the polymorphic form of precipitated CBZ particles. The minimum 
operating pressure was decided based on the previous work by Padrela et al. in 2017, which 
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reported that CBZ precipitates from methanol solutions when operating pressures of 90 bar 
and above are used in the GAS process. 16 Although precipitation was reported to occur at 
pressures below 90 bar, this value was selected to ensure that all CBZ samples would 
effectively precipitate and particles would be collected at the end of each experiment. 
Additionally, the critical pressure for CO2 (74.8 bar) also influenced our selection of the 
minimum operating pressure, to ensure that we are using CO2 in the supercritical state. 
The final variable chosen for this study was the antisolvent (scCO2) addition rate.  Antisolvent 
addition rate has been reported in the literature to impact the final particle size of APIs,46 
however this paper aims to investigate if this variable has an impact on the final polymorphic 
form of CBZ obtained in a GAS process. This variable influences the crystallization kinetics, 
as supersaturation will be achieved quicker at higher antisolvent addition rates. Padrela et 
al. reported that using supercritical antisolvent techniques such as gas antisolvent (GAS), in 
combination with anionic additives, it is possible to accurately control the polymorphism of 
CBZ at specific conditions (90 bar, 40 °C, 70 mg/ml). 16 The study presented herein 
investigates if this control can be extended over a wide range of critical operating variables 
compared to the specific conditions reported previously. Additionally, this paper investigates 
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if polymorphic transformations are likely to occur for CBZ after it has crystallized by GAS, 
while immersed in scCO2-methanol mixtures over an extended period of time. 
Figure 3 presents the Design of Experiments (DoE) approach undertaken for this study using 
the previously mentioned operating process variables (e.g. temperature, pressure and CO2 
antisolvent addition rate). An initial DoE was completed without the use of additives to 
determine a control result for the polymorph of CBZ generated. Following completion of this, 
the anionic additives sodium stearate and sodium dodecyl sulfate were used at quantities of 
5% w/w. 
Figure 3. Design of Experiments (DoE) schematic investigating the effect of temperature, pressure 
and CO2 addition rate on the polymorphic form of CBZ with/without using distinct additives (e.g. 
sodium stearate, sodium dodecyl sulfate).
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The results from this DoE, shown in Figure 4, emphasize that very little systematic control 
can be achieved in this system (CBZ and methanol) across a wide range of operating 
conditions, when additives are not used. 
Figure 4. a) Design of Experiments (DoE) schematic to investigate the polymorphic outcome of CBZ 
in a GAS process without the use of additives, using pressure, temperature and antisolvent addition 
rate as the process variables. b) Powder X-ray diffraction patterns of theoretical CBZ polymorphic 
forms (I, II, and III) from the Cambridge Structural Database (CSD) and CBZ samples processed 
(without additives) by the GAS method. Experimental conditions as described in Table 1 (DoE Points 
1-9).
The introduction of form I at DoE Point 6 at 70 °C is likely due to the proximity of this value 
to the reported transition temperature between CBZ form I and form III. Although form III is 
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present in all samples, either as a PXRD-pure form or an impurity, no clear trend can be 
observed to determine what polymorphic form will be produced at each condition. Statistical 
analysis of this DoE is discussed in the supporting information. A similar DoE approach to 
examine the polymorphic control of CBZ, provided by anionic additives, is investigated 
below. 
Figure 5 describes the results of another DoE which explores the GAS process variables 
(e.g. pressure, temperature and CO2 antisolvent addition rate) over a wide range of 
conditions using the anionic additive sodium stearate (SS). This additive has previously been 
shown to control the polymorphism of CBZ in both batch (GAS) and continuous (SASD) 
supercritical antisolvent processes, at specific processing conditions.16, 47 
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Figure 5. a) Design of Experiments (DoE) schematic to investigate the polymorphic outcome of CBZ 
in a GAS process using sodium stearate as the additive and using pressure, temperature and antisolvent 
addition rate as the process variables. b) Powder X-ray diffraction patterns of theoretical CBZ 
polymorphic forms (I, II, and III) from the Cambridge Structural Database (CSD), SS and CBZ 
samples processed by the GAS method with SS as the additive. Experimental conditions as described 
in Table 1 (DoE Points 10-18).
The mechanistic details of the role of these additives on the polymorphic control of CBZ have already 
been proposed by Padrela et al., however, exploring how robust this control is across a range 
of process conditions in the GAS method has not yet been addressed. The results of this 
DoE confirm that SS generates CBZ form II in GAS across a wide range of temperatures, 
pressures and antisolvent addition rates. From the patterns in Figure 5 (b), we observe 
PXRD-pure form II at each condition explored. These results indicate that the templating of 
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CBZ molecules by SS, during the pre-nucleation stage in a CO2 antisolvent process such as 
GAS, occurs across the wide range of critical operating conditions selected in this study.
In Figure 6, sodium dodecyl sulfate (SDS) was selected as an additive to investigate if the 
stable form of CBZ (form III) could be obtained across the same operating conditions as 
described previously in Figures 4 and 5. 
Figure 6. a) Design of Experiments (DoE) schematic to investigate the polymorphic outcome of CBZ 
in a GAS process using sodium dodecyl sulfate (SDS) as the additive, and using pressure, temperature 
and antisolvent addition rate as the process variables. b) Powder X-ray diffraction patterns of 
theoretical CBZ polymorphic forms (I, II, and III) from the Cambridge Structural Database (CSD), 
SDS and CBZ samples processed by the GAS method with SDS as the additive. Experimental 
conditions as described in Table 1 (DoE Points 19-27).
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These results highlight the exceptional control achieved on the polymorphism of CBZ when 
using SDS as the additive at 5% w/w. The stable form III is obtained for almost every point 
on the DoE in Figure 6. The only exception is for DoE Point 24 where the presence of small 
diffraction peaks from the metastable form II at 5 ° and 9 ° (2 Theta) can be observed. The 
presence of peaks (approximately 6 and 7.5 ° 2 Theta) at DoE Points 20 and 21 appear to 
correspond to the molecular additive (SDS) used for this study. As this value is close to the 
transition temperature between form I and form III at 70 °C, we propose that the change in 
stability of form III provides an opportunity for metastable polymorphs, such as CBZ form II, 
to appear in the sample. Despite these stability differences at this temperature (70 °C), DoE 
Point 24 is the only experiment where we have observed the presence of impurities from 
other polymorphic forms in the final sample.
Particle Shape of CBZ Crystals Produced by GAS Using Anionic Additives
Figure 7 depicts SEM images of a specific CBZ form II sample (DoE Point 14) produced by 
the GAS method using sodium stearate as the additive (conditions as described in Table 1). 
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Figure 7. Scanning electron microscopy (SEM) images of CBZ particles produced by the GAS 
method using sodium stearate as the additive (DoE Point 14): a) CBZ form II (x450); b) CBZ form II 
(x1000); c) CBZ form II (x4500) and d) CBZ form II (x8000).
The shape of these CBZ particles can be described as needle-like, which corresponds well 
with existing literature for the crystal shape of CBZ form II.48 The average size of these 
particles varies as larger needles can be observed in most samples but typically range from 
about 1-10 µm in width and approximately 5-500 µm in length. The presence of smaller rod 
shaped particles on the crystal surface (particularly visible in Figure 7 (c) and (d)), produce 
an increased level of elemental sodium (the only element unique to each additive) detected 
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by EDS analysis at these localized areas. This result is discussed in greater detail in the 
supporting information.
Figure 8 depicts SEM images of DoE Point 23, produced using 5% w/w SDS by the GAS 
method (conditions as described in Table 1). 
Figure 8. Scanning electron microscopy (SEM) images of CBZ particles produced by the GAS 
method using SDS as the additive (DoE Point 23): a) CBZ form III (x100); b) CBZ form III (x500); 
c) CBZ form III (x1000) and d) CBZ form III (x4000).
These CBZ particles are block-shaped which corresponds well to the reported shape for this 
polymorph (form III).49 These CBZ form III crystals appear to have greater uniformity, when 
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compared to the particles in Figure 7. The average particle size in this sample (DoE Point 
23) is approximately between 20-25 µm. Unlike Figure 7, the presence of smaller additive 
particles is not observed in this sample. This result is supported by EDS analysis, which does 
not detect a localized area of sodium. The location of additive particles, with respect to 
sodium stearate samples, is discussed in the supporting information. 
Stability of CBZ Particles Precipitated by GAS Immersed in scCO2-Methanol Mixtures
An investigation into the thermodynamic stability of precipitated CBZ particles was performed 
to determine the extent of the polymorphic control exhibited by anionic additives (SS, SDS). 
To perform this, the drug suspension (CBZ, additive and methanol) remained immersed in 
scCO2 for a period of sixty hours. Understanding the extent of this polymorphic control 
exhibited by anionic additives may be crucial for API processing with the prospect that the 
drug may be suspended in a reactor for a longer time than scheduled due to unforeseen 
circumstances in industrial environments. This period (sixty hours) was deemed adequate to 
investigate if polymorphic transformation would occur in supercritical media. 
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Figure 9 shows a long-hold DoE study without the use of additives. The results of this DoE 
compared to Figure 4 (short hold DoE) indicate that polymorphic conversions of CBZ in 
mixtures of methanol and CO2 are likely to occur depending on the amount of time immersed 
in scCO2. 
Figure 9. a) Design of Experiments (DoE) schematic to investigate the polymorphic conversion of 
CBZ in scCO2-methanol mixtures without using additives, using pressure, temperature and antisolvent 
addition rate as the GAS process variables over an extended period (sixty hours). b) Powder X-ray 
diffraction patterns of theoretical CBZ polymorphic forms (I, II, and III) from the Cambridge 
Structural Database (CSD) and CBZ samples processed (without additives) by the GAS method. 
Experimental conditions as described in Table 2 (DoE Point 28-36). Short hold DoE (Figure 4) 
included for comparison.
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These results show that some CBZ samples from the DoE points presented in Figure 9 begin 
to convert from impure polymorphic mixtures (DoE points 3, 4 and 5 from Figure 4) to PXRD-
pure form III (DoE points 30, 31 and 32 from Figure 9), which is the stable form at this 
temperature. Interestingly, two DoE Points (33 and 36) which lie close to the transition 
temperature between form I and III are the only values in this DoE that show no evidence of 
form III. The mixture of CBZ forms I, II and III from DoE point 6 (short hold DoE from Figure 
4) converted to PXRD-pure form I (DoE point 33 from Figure 9), while the PXRD-pure form 
III from DoE point 9 (Figure 4) converted to a mixture of forms I and II (DoE point 36 from 
Figure 9). This result (conversion from a stable form to metastable) may be explained by the 
close proximity to CBZ form I and III transition temperature. This presence of another 
metastable form (CBZ form II) requires further investigation to understand why the 
introduction of this form occurs during a long hold study.  The reduced stability of form III at 
this temperature likely explains the presence of form I, but may also be a contributing factor 
towards the presence of CBZ form II. 
Page 32 of 43
ACS Paragon Plus Environment






























































Figure 10 investigates the effect that increased hold-time of CBZ in scCO2-methanol 
mixtures has on the polymorphic outcome of CBZ obtained when sodium stearate (SS) is 
used as an additive at 5% w/w. 
Figure 10. a) Design of Experiments (DoE) schematic to investigate the polymorphic conversion of 
CBZ in in scCO2-methanol mixtures using the anionic additive sodium stearate (SS), using pressure, 
temperature and antisolvent addition rate as the GAS process variables over an extended period (sixty 
hours). b) Powder X-ray diffraction patterns of theoretical CBZ polymorphic forms (I, II, and III) 
from the Cambridge Structural Database (CSD) and CBZ samples processed (with SS) through the 
GAS method. Experimental conditions as described in Table 2 (DoE Points 37-45). Short hold DoE 
(Figure 5) included for comparison.
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The results show that at lower temperatures (40° C), the metastable form II begins to convert 
to the stable form III (DoE Points 37-40), resulting in PXRD-pure form III at higher pressures 
(170 bar) and a mixture of forms II and III at lower pressures (90 bar). Denser scCO2 (CO2 
at higher pressures) has been shown to promote crystallization reactions when compared to 
CO2 at lower pressures.19 This may provide an explanation to why complete polymorphic 
transformations are observed at higher pressures, while partial transformations are observed 
at lower pressures.  At higher temperatures (70 °C), close to the transition temperature 
between forms I and III, no polymorphic transformations occur and PXRD-pure form II is still 
observed. As the stability of form III is reduced at these high temperatures, there is less of a 
tendency for metastable forms (I and/or II) to convert to stable forms, which can be observed 
in Figure 10.
The final DoE (Figure 11) investigates the effect that hold-time of CBZ in scCO2-methanol 
mixtures has on the polymorphic outcome of CBZ obtained when sodium dodecyl sulfate 
(SDS) is used as an additive at 5% w/w. The DoE in Figure 11 shows minimal conversion of CBZ 
form III when compared to the short hold DoE in Figure 6. 
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Figure 11. a) Design of Experiments (DoE) schematic to investigate the polymorphic conversion of 
CBZ immersed in scCO2-methanol mixtures using the anionic additive sodium dodecyl sulfate (SDS), 
using pressure, temperature and antisolvent addition rate as the GAS process variables over an 
extended period (sixty hours). b) Powder X-ray diffraction patterns of theoretical CBZ polymorphic 
forms (I, II, and III) from the Cambridge Structural Database (CSD) and CBZ samples processed (with 
SDS) through the GAS method. Experimental conditions as described in Table 2 (DoE Point 46-54). 
Short hold DoE (Figure 6) included for comparison.
This result is expected, as it is unlikely to observe significant polymorphic conversions when the 
initial polymorph obtained (figure 6) was the stable form (at room temperature). From the short hold 
DoE in Figure 6, only one sample (DoE point 24) contained a mixture of two polymorphic forms (II 
and III). When the CBZ in scCO2-methanol mixture was allowed to remain in the reactor for an 
extended period, PXRD-pure form III was produced. The presence of form III crystals at short hold 
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points (DoE point 24) may have acted as a seed to promote the conversion of CBZ from forms II and 
III to PXRD-pure form III in the long hold study, despite the reduced stability. In the DoE presented 
in Figure 11, point 54 converts from PXRD-pure form III (point 27 in Figure 6) to a mixture of forms 
I and III. Unsurprisingly, this point (DoE Point 54) occurs at 70 °C, close to the transition temperature 
between these polymorphs, which may explain why this mixture was formed. The minimal 
polymorphic transformations that occur between Figures 6 and 11 highlights both the control provided 
by SDS as well as the thermodynamics of the CBZ system. Similarly to what was observed in the 
short hold-time DoE using SDS (Figure 6), PXRD peaks from the additive used (SDS) can be observed 
in several diffraction patterns of CBZ samples from the long hold DoE (DoE Points 47, 48, 49 and 
53) from Figure 11.
An additional study, which investigates the impact that the quantity of a different additive (ethyl 
cellulose) has on the polymorphic form of CBZ obtained by GAS methods is presented and discussed 
in the supporting information. In 2017, Padrela et al. proposed the mechanistic details that gave rise 
to the formation of CBZ form II when using sodium stearate (SS), and to the formation of CBZ form 
III when using sodium dodecyl sulfate (SDS).16 Those models, generated using density functional 
theory calculations, described the interaction between CBZ and additive molecules at a ‘pre-
nucleation’ stage, which led to the selective formation of either CBZ form II or III. We propose that 
the mechanisms described by Padrela et al in 201716 appear to be upheld for, not only a specific set 
of conditions but also a wide range of critical processing variables. This observation is based on the 
results obtained from figures 5 and 6 as well as the minimal polymorphic conversions taking place in 
Figures 10 and 11 (long hold DoEs with the additives SS and SDS, respectively) compared to Figure 
9 (DoE without additives).
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This manuscript demonstrates that process variables such as temperature and antisolvent addition rate 
can influence the polymorphism of CBZ in a gas antisolvent (GAS) method when additives are not 
selected. This study was performed using a Design of Experiments (DoE) approach in conjunction 
with statistical analysis. Both approaches indicated that when additives were not used, the 
combination of temperature and antisolvent addition rate were major influencing factors (p < 0.05) 
with respect to polymorphism (see supporting information).  However, when two anionic additives, 
either sodium stearate (SS) or sodium dodecyl sulfate (SDS), were added in 5% w/w amounts, 
polymorphic control of CBZ across a wide range of processing variables was achieved.  
Samples that were observed to contain mixtures of two or more polymorphic forms of CBZ primarily 
occurred at the higher temperature range (70 °C). Interestingly, this temperature value is close to the 
transition temperature between forms I and III (~ 71 °C). The reduced stability of form III at this 
temperature may allow for the introduction of impurities from other polymorphic forms to emerge in 
the final CBZ samples. 
An investigation into the stability of precipitated CBZ particles was also performed where the 
crystallized drug suspension would remain immersed in scCO2 for a period of sixty hours. At low 
temperatures without additives it was observed that CBZ form III (the stable form at room 
temperature) became the dominant polymorph produced. Even when sodium stearate (which promotes 
the formation of CBZ form II) was used, partial to complete conversions at low temperatures (40° C) 
from form II to form III were observed after sixty hours. Sodium dodecyl sulfate promoted the 
formation of form III during short-hold processing and, as a result, minimal polymorphic conversions 
were observed during longer hold times. Long hold DoEs using additives highlight that control over 
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polymorphism can still be achieved during extended periods. However, this control is not as 
comprehensive as observed with shorter hold times.
Overall, CBZ forms II and III can be readily produced using a gas antisolvent (GAS) technique by 
using anionic additives, regardless of the processing conditions used (pressure, temperature and CO2 
addition rate). These additives (SS and SDS) influence the final polymorphic form obtained at both 
short and long hold times. Statistical analysis is used in this study to demonstrate that this control is 
not achieved comprehensively in the absence of anionic additives, SS and SDS. 
Supporting Information
Statistical analysis and SEM-EDS characterization of the DoEs described in the manuscript 
are available in the supporting information. An additional DoE investigating ethyl cellulose at 
different additive concentrations (1% and 10%) is also available.
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